definiens: means each ( a ) Compound that [COMPANY] determines during the ResearchProgram Term to have Minimum Binding Affinity or ( b ) compound Derived therefrom by or on behalf of [COMPANY] orTargacept ( including, for clarification, any compounds Derived from an Active+ Compound, Collaboration Compoundor Candidate Drug ( excluding Ispronicline ( or any Licensed Derivatives with respect thereto ) and Option CompoundCandidate Drugs ) ) during the Research Program Term or the Tail Period if such Derived compound ( i ) itself hasMinimum Binding Affinity or ( ii ) is not the [ * * * * * * * * ] where an objective of the [ * * * * * * * * ], in whole or in part, was to [ * * * * * * * * ] ; including in each case ( ( a ) and ( b ) ) any salt form, polymorph, crystalline form, hydrate, solvate orformulation thereof . Notwithstanding the foregoing, unless the Parties otherwise agree in writing, the Compoundsknown to [COMPANY] as of the Execution Date as [ * * * * * * * * ] and [ * * * * * * * * ] and, [ * * * * * * * * ], including any salt form, polymorph, crystalline form, Prodrug, metabolite ( other than any such metabolite that is an Excluded ZoneCompound ), hydrate, solvate or formulation thereof, shall not be Collaboration Candidates